Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large decline in short interest in August. As of August 31st, there was short interest totalling 228,000 shares, a decline of 6.2% from the August 15th total of 243,100 shares. Based on an average daily trading volume, of 163,500 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.9% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday, August 15th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. purchased a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned about 0.09% of Bolt Biotherapeutics as of its most recent SEC filing. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Stock Performance

BOLT traded up $0.01 on Wednesday, hitting $0.64. The company had a trading volume of 15,264 shares, compared to its average volume of 172,875. The company’s fifty day moving average price is $0.70 and its 200 day moving average price is $0.90. Bolt Biotherapeutics has a 1-year low of $0.61 and a 1-year high of $1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.28 and a quick ratio of 4.28. The stock has a market cap of $24.58 million, a price-to-earnings ratio of -0.38 and a beta of 0.93.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative return on equity of 61.40% and a negative net margin of 592.57%. The business had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.19 million. Equities analysts predict that Bolt Biotherapeutics will post -1.44 earnings per share for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.